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Abstract 
During the lactation, the choice of a proper antibiotic is crucial since the drug can cross into breast 
milk causing toxicity to the infant. Therefore, an extraction protocol and LC/MS-MS method for the 
determination of daptomycin in human milk and plasma were developed, validated and applied to a 
case of a breastfeeding mother affected by a purulent acute soft skin infection treated with 
daptomycin. Because of daptomycin high protein binding and its high molecular weight, the 
optimisation of the extraction protocol and analytical conditions were deeply investigated, and 
several parameters were taken into account: in particular the type of extraction, internal standard, 
the type of organic modifier, pH of the aqueous solution, and gradient. The use of a protein 
precipitation protocol coupled to a C8-reverse phase LC-MS/MS allows for a reliable quantification 
of daptomycin in both plasma (in the range of 19-199 g/ml) and breast milk (in the range of 0.12-
0.32 µg/ml). The determination of milk/plasma (M/P) ratio, which ranged from 0.002 to 0.006, 
allowed to assess that daptomycin, effective for the mother, was contemporarily safe for the 
breastfed newborn. 
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1. Introduction 
Daptomycin is a cyclic lipopeptide antibiotic with a molecular weight of 1620.67 Da, produced by 
Streptomyces roseosporus, with established activity against aerobic and anaerobic Gram-positive 
pathogens [1,2]. The daptomycin mechanism of action is unique since it binds to the bacterial cell 
membrane causing a potassium efflux which leads to its depolarization. Disruption of DNA, RNA 
and protein synthesis subsequently occurs provoking rapid concentration-dependent pathogen death 
[3,4]. Daptomycin is mostly distributed in the extracellular fluid since it cannot cross the cell 
membrane. The drug displayed an extensive (90-93%) but reversible bound to serum albumin and 
human plasma proteins in a concentration-independent manner [5]. 
Daptomycin was authorised in 2003 by the FDA for the treatment of 1) complicated skin and skin 
structure infections at a dose of 4 mg/kg every 24 hours intravenously, and 2) bloodstream 
infections (bacteraemia) at a dose of 6 mg/kg every 24 hours intravenously [6]. 
From an analytical point of view, in the literature, some HPLC methods to determine this antibiotic 
in biological fluids such as serum [7-9], plasma [10-13] and blood [14] are reported.  
To the best of our knowledge, a unique case report has been published on daptomycin concentration 
in human milk after parenteral administration to the nursing mother [15]. Therefore, we developed 
and validated an extraction protocol and UPLC/MS-MS method for the determination of 
daptomycin in human milk and plasma, that was applied to a case of a breastfeeding mother 
affected by a purulent acute soft skin infection treated with daptomycin caused by methicillin-
resistant Staphylococcus aureus (MRSA) [16]. Due to the increasing resistance of bacteria to these 
antimicrobial drugs, the choice of the appropriate drug can be crucial. The possible excretion of the 
antibiotic into milk, during breastfeeding, must be considered by clinicians to avoid side effects in 
the child [17]. Thus, the calculation of the milk/plasma (M/P) ratio was necessary to evaluate 1) the 
efficiency of daptomycin for the mother and 2) the Relative Infant Dose (RID) for the breastfed 
newborn. 
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2. Materials and methods 
 
2.1 Reagents and chemicals 
Methanol, acetonitrile, formic acid, ammonium formate, reserpine (all analytical grade > 99%) were 
purchased from Sigma-Aldrich (St.Louis, USA). Standard solution of daptomycin and erythromycin 
were prepared using certified reference material purchased from Sigma-Aldrich (St.Louis, USA). 
Water (18.2Ω cm-1) was prepared using a Milli-Q System (Millipore, Darmstadt, Germany).   
 
2.2 Preparation of standard stock solutions 
Daptomycin standard stock solution was obtained dissolving 1 mg of daptomycin in 1 ml methanol. 
This solution was diluted in methanol 1:10, 1:100 or 1:1000 gaining working solutions 100 g/ml, 
10 g/ml and 1 g/ml respectively. Erythromycin standard stock solution was obtained dissolving 1 
mg of erythromycin in 1 ml methanol. This solution was diluted in methanol 1:100 or 1:1000 
gaining working solutions 10 g/ml (IS used for plasma samples) and 1 g/ml respectively (IS used 
for milk samples). Stock solutions were stored at 2-8°C, protected from direct light in amber glass 
containers.  
 
2.3 Clinical samples 
Five blood samples and nine breast milk samples were collected from a neo-mother hospitalized for 
complicated erysipelas of the left arm. Breast milk was obtained by breast milk pumping machine 
whereas plasma was harvested from blood by centrifugation (10 000 xg for 10 min).  The 
therapeutic plan consisted of 14 days of intravenous administration of daptomycin 500 mg/day 
coupled with meropenem 1g/3 times a day. The pharmacological study was limited to 5 days: the 
last four days of treatment and the following one free of therapy. Each sample represents a different 
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time-point and they were referred as hours after the eleventh administration of daptomycin which 
was considered our time-zero point (T0).  Daptomycin was administered at 0, 24, 48 and 72 hours. 
Breast milk samples were collected at nine time-points: 0, 6, 12, 48, 72, 78, 84, 96 and 120 hours. 
Plasma samples were collected at five time-points: 72, 78, 84, 96 and 120 hours.  
 
2.4 Sample pre-treatment 
2.4.1 Plasma extraction 
100 L of plasma were diluted with 900 L saline. 100 L of diluted plasma was added with 100 
L of IS (erythromycin in methanol solution 1 g/mL) and 200 L of methanol. Samples were 
sonicated in an ultrasonic bath for 15 minutes and centrifuged for 10 min at 0.805 x g. The 
supernatant was withdrawn, centrifuged for others 15 min at 0.805 x g and filtered on a 0.45 m 
nylon filter membrane. 10 L were injected for LC/MS-MS analysis. 
2.4.2 Breast milk extraction 
200 L of breast milk was added with 100 L of IS (erythromycin in acetonitrile solution 10 
g/mL) and 300 L of acetonitrile. Samples were sonicated in an ultrasonic bath for 15 minutes and 
centrifuged for 15 min at 0.805 × g. The supernatant was withdrawn, centrifuged for others 10 min 
at 0.805 x g and filtered on a 0.45 m nylon filter membrane. 10 L were injected for LC/MS-MS 
analysis. 
 
2.5 Preparation of sample for method validation 
Standard samples containing different daptomycin amounts (for breast milk 100, 250, 500 and 750 
ng/ml and plasma 0.25, 5, 10 and 25 g/ml)   were prepared by adding suitable volumes of working 
solutions of daptomycin to drug-free plasma (100 L) or milk (200 L). The standard samples for 
method validation were treated as reported in the “sample pre-treatment” section.  
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2.6 LC/MS-MS conditions 
The analytical system consisted of an HPLC coupled to a tandem mass spectrometer. The liquid 
chromatography system was an Acquity UPLC Class System (Waters Corporation, Manchester, 
UK) equipped with two chromatographic pumps and an autosampler. Separation was attained on a 
reversed-phase Agilent Poroshell 120 SB-C8 100 mm x 2.1 mm x 2.7 m particle size (Santa Clara, 
USA) analytical column, preceded by a security guard cartridge. For plasma samples, the linear 
gradient was between eluent A (ammonium formate 10mM + 0.1% formic acid) and eluent B 
(acetonitrile). The column was equilibrated with 20% (B) for 2 min and increased to 80% (B) in 1 
min, held for 5 min, back to the initial conditions in 1 min and kept for 1 min at 20% (B). The 
retention times were 3.30 (daptomycin) and 3.50 (IS)  0.3 min. For breast milk samples the linear 
gradient was between eluent A (water + 0.1% formic acid) and eluent B (acetonitrile). The column 
was equilibrated with 5% (B) for 3 min and increased to 99% (B) in 0.2 min, held for 3 min, back to 
the initial conditions in 1 min and kept for 2 min at 5% (B). The retention times were 4.30 
(daptomycin) and 4.32 (IS)  0.3 min. The flow rate was 0.3 mL/min and the column oven was kept 
at 40°C. The tandem mass spectrometer was a triple quadrupole Acquity TQD by Waters 
Corporation (Milford, USA) with electrospray ionization (ESI) Z-spray ion source.  Instruments 
were managed with the proprietary manufacturer's software MassLynx 4.1 according to the 
manufacturer's instructions. The capillary voltage was set at 1.5 kV and the source temperature was 
set at 150 °C. The dwell time was set at 0.3 s, and the MS analysis was performed in positive ion 
mode (ESI+). Nitrogen was used as desolvation and cone gas with a flow of 500 L/h at 350°C, 
whereas argon as collision ones. The product ion spectrum (MS-MS) of each analyte was generated 
via direct infusion to obtain optimised compound-dependent parameters (Table 1): cone voltage (V) 
and collision energies (eV). Multiple reaction monitoring (MRM) mode was used. 
3. Results and Discussion 
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3.1 Method development 
3.1.1 Internal standard  
The choice of internal standard ranged between reserpine (from literature) and erythromycin. 
Reserpine was immediately discharged due to its strong insolubility in water. Despite the structural 
diversity, erythromycin and daptomycin showed a similar behaviour during extraction and 
chromatographic separation (see paragraphs below, Figure 1).  
3.1.2 Extraction optimisation  
Different approaches were tried such as solid-phase extraction (SPE) and precipitation technique 
(using methanol and acetonitrile) for determination of daptomycin in biological matrices. SPE was 
performed using polymeric phase OASIS HLB cartridges (Waters Corporation, Manchester, UK). 
Before use, the cartridges were conditioned with 2 mL methanol and 2 mL deionized water. After 
sample loading, the cartridges were then rinsed with 2 mL deionized water with 5% methanol and 
vacuum-dried for 5 min to remove excess water. Then, the retained compounds were eluted with 2 
mL of methanol and the eluate was evaporated until dryness. Finally, it was reconstituted with 
phase B. Captiva NDlipid filtration plates (Agilent Technologies, Santa Clara, CA) were evaluated in 
order to retain undesirable matrix interferences, lipids and proteins. 50-200 µL of the biological 
matrix was added with methanol acidified with 0.1% formic acid (1:3) and vacuum-filtered. The 
eluate was collected in a test tube and evaporated. These procedures demonstrated an incomplete 
recovery of analytes, due to their weak interactions with SPE phase and their high hydrophilic 
nature. Process efficiencies (calculated according to Matuszewski [18]) were for SPE about 40% 
and for filtration plates about 18%. A simple protein precipitation protocol (described in “sample 
pre-treatment”) fulfilled the expectation and was employed in the extraction of daptomycin in 
plasma and milk samples using as precipitation agents methanol and acetonitrile respectively. 
Process efficiencies [18] were evaluated in plasma 77±1.5% (n=3) for erythromycin and 81±2.7% 
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(n=3) for daptomycin respectively whereas for breast milk 79±3.5% (n=3) for erythromycin and 
85±5.1.% (n=3)  for daptomycin. 
3.1.3 Chromatographic optimisation  
To optimise the proposed LC–MS/MS method, the effects of several chromatographic parameters 
were investigated. These included the type of organic modifier, pH of the aqueous solution, and 
gradient. These parameters were optimised based on the peak shape, peak area, peak resolution and 
retention time for the analytes on Agilent Poroshell 120 SB-C8 (100 mm x 2.1 mm x 2.7 m) 
column. Regarding organic modifier, methanol and ethanol were evaluated, but acetonitrile was 
found to have better performances in peak shape and resolution. Moreover, the introduction of 
ammonium formate (5-10 mM) and formic acid (0,1%) in organic phase did not provide any 
benefits. Importantly it has been noticed that the peak shape and the intensity of noise were matrix-
dependent and correlated with % of eluent A during the chromatographic run. Thus, eluent A was 
changed between plasma and milk samples using ammonium formate 10mM + 0.1% formic acid 
and water + 0.1% formic acid respectively. In the same way, the gradient was adjusted as described 
in “LC/MS-MS conditions” (Figure 2). 
 
3.2 Method validation 
Validation protocol, adapted from EMEA guideline [19], included parameters such as specificity, 
precision, accuracy, linearity, limit of detection (LOD) and limit of quantification (LOQ). The 
specificity was assessed, in both plasma (n=6) and milk (n=6), by extracting blank control samples, 
control blank samples added in IS and solvents in each validation run. The lack of interfering peaks 
at the same analyte retention times was considered as an acceptable selectivity (Figure 3). LOQ is 
the lowest concentration that met at least five times the signal of a blank sample. LOD was not 
defined by EMEA guidelines, thus it was considered as the value that encounters a signal-to-noise 
(evaluated by MassLynx 4.1 software) ratio greater than 3 [20]. Validation parameters for precision 
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and accuracy were calculated using different replicates of samples in different working days. 
Accuracy was expressed as the percent recovery (REC%), while precision was measured as 
coefficient of variation (CV%). A CV% below 10% and REC% between 80-120% were considered 
suitable. Accuracy and precision were determined at four different concentration at LOQ, low, 
medium and high depending on matrixes: for breast milk 100, 250, 500 and 750 ng/ml and for 
plasma 0.25, 5, 10 and 25 g/ml respectively. Five-point matrix-matched calibration curves were 
calculated by plotting peak area of quantifier ion of daptomycin/area IS (erythromycin) vs the total 
amount of daptomycin added in the range 0.25-200 μg/ml for plasma samples 100-1000 ng/ml for 
milk ones. The linearity was proven according to the regression line by the method of least squares 
and expressed by the coefficient of correlation (R2). Method validation results were listed in Table 
2. 
 
3.3 Application on clinical samples 
The validated method was successfully applied to quantify daptomycin in plasma and milk of a 
patient. To ensure a reliable instrumental performance clinical samples were run with day quality 
control samples (LOQ, low, medium and high) and blank samples. The concentration of 
daptomycin in these clinical samples fall within the linearity range of the method in both matrixes: 
plasma samples ranged between 19 to 199 g/ml whereas milk ones between 0.12 to 0.32 µg/ml 
(Table 3). The aim was to identify its accumulation in milk and the related toxicity for the child 
after breastfeeding. From obtained results, daptomycin excretion in milk was confirmed and marked 
differences in concentration were observed between the two different biological matrices (Figure 4). 
Cmax was found to be, at 78h after the eleventh administration, with a concentration of 199 µg/mL in 
plasma and 0.329 µg/mL in milk. Moreover, milk/plasma concentration ratio (M/P) was calculated 
in order to investigate an eventual bio-distribution in milk and a maximum of 0.05 was found [16]. 
These M/P ratios (<<1) indicate an irrelevant accumulation in milk with no significant toxicity for 
  
9 
the child. AUC calculated in the final region of the pharmacokinetics profile (AUC72-120h) agrees 
with previous findings:  3315 for plasma vs 11.3 for milk. For ethical reasons, daptomycin could 
not be quantified, as a direct evaluation, in blood samples from the child. However, the theoretical 
absolute infant dose (AID) was calculated as the product of the median milk concentration and 
assumed milk intake of 0.15 l kg-1 day-1 resulting 36.5 µg kg-1 day-1. The relative infant dose 
estimated as AID expressed as a percentage of the maternal dose in μg kg–1 day–1, was 0.50%, well 
below the most common accepted cut-off of 10% of the weight-adjusted maternal dose [16]. 
Overall, these data suggested that daptomycin is excreted into human milk at a low concentration 
due to daptomycin’s high protein binding and its high molecular weight.  
The determination of milk/plasma (M/P) ratio, which ranged from 0.002 to 0.006, allowed to assess 
that daptomycin was effective for the mother, in accordance with the study by Dvorchik et al. [10] 
in which safety and tolerability of daptomycin were evaluated by monitoring adverse events (AEs) 
and laboratory parameters. Daptomycin pharmacokinetics was linear through 6 mg/kg. Daptomycin 
protein binding (mean amount bound, 91.7%) was independent of the drug concentration. No 
gender effect was observed and there were no serious AEs and no pattern of dose-related events. 
Daptomycin was well tolerated when it was administered once daily at a dose as high as 8 mg/kg 
for 14 days. Daptomycin was contemporarily safe for the breastfed newborn as highlighted in the 
study by Buitrago et al. [15], in which a case of pelvic inflammatory disease (PID) caused by 
methicillin-resistant Staphylococcus aureus, in a breastfeeding mother who was successfully treated 
with daptomycin is described. Daptomycin concentrations in her breast milk were measured to 
determine potential exposure to her infant. These concentrations were extremely low, with an 
estimated milk:plasma ratio of 0.0012, in accordance with the values calculated in the present study. 
So, as the authors conclude, although additional confirmatory studies are needed, daptomycin may 
be a reasonable option in the treatment of PID caused by gram-positive organisms that are resistant 
to other antibiotics. 
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5. Conclusions 
An extraction protocol and UPLC/MS-MS method for the determination of daptomycin in human 
milk and plasma was developed, validated and applied to a case of a breastfeeding mother affected 
by a purulent acute soft skin infection treated with daptomycin. Daptomycin excretion in milk was 
confirmed, but marked differences in concentration were observed between the two different 
biological matrices. M/P was calculated and a maximum of 0.05 was found. These M/P ratios (<<1) 
indicate an irrelevant retaining in milk with no significant toxicity for the child [16].   
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Tables 
Table 1. Mass spectrometry conditions for each analyte, in bold transition used for quantification 
Analytes Transition  Cone (V) Collision (eV) 
Daptomycin 811.10 > 341.00 36 56 
 811.10 > 159.13 36 34 
 811.10 > 313.26 36 26 
Erythromycin (IS) 733.00 > 158.09 34 32 
 
Table 2. Method validation results in both plasma and breast milk samples.  
 
Parameters Plasma Breast milk 
LOD 0.10 µg/ml 50 ng/ml 
LOQ 0.25 µg/ml 100 ng/ml 
Precision 
Intraday (overall) 
   LOQ 
   Low  
   Medium  
   High 
 
Interday (overall) 
   LOQ 
   Low 
   Medium 
   High 
 
CV%=3.5 (n=12) 
CV%=6.1 (0.25 µg/ml, n=3) 
CV%=1.9 (5 g/ml, n=3) 
CV%=0.2 (50 g/ml, n=3) 
CV%=5.7 (100 g/ml, n=3) 
 
CV%=6.0 (n=24) 
CV%=7.5 (0.25 µg/ml, n=6) 
CV%=4.2 (5 g/ml, n=6) 
CV%=5.7 (50 g/ml, n=6) 
CV%=6.7 (100 g/ml, n=6) 
 
CV%=3.7 (n=12) 
CV%=7.4 (100 ng/ml, n=3) 
CV%=5.2 (250 ng/ml, n=3) 
CV%=1.4 (500 ng/ml, n=3) 
CV%=1.1 (750 ng/ml, n=3) 
 
CV%=4.8 (n=24) 
CV%=7.4 (100 ng/ml, n=6) 
CV%=4.1 (250 ng/ml, n=9) 
CV%=5.4 (500 ng/ml, n=9) 
CV%=4.8 (750 ng/ml, n=9) 
Accuracy 
Intraday (overall) 
   LOQ 
   Low 
   Medium 
   High 
 
Interday (overall) 
  LOQ 
   Low 
   Medium 
                High 
 
REC%=105 (n=12) 
REC%=105.0 (0.25 g/ml, n=3) 
REC%=98.5 (5 g/ml, n=3) 
REC%=111.1 (50 g/ml, n=3) 
REC%=105.6 (100 g/ml, n=3) 
 
REC%=108.9 (n=24) 
REC%=108.0 (0.25 g/ml, n=3) 
REC%=109.2 (5 g/ml, n=6) 
REC%=111.1 (50 g/ml, n=6) 
REC%=106.5 (100 g/ml, n=6) 
 
REC%=108.5 (n=12) 
REC%=113.2 (100 ng/ml, n=3) 
REC%=112.4 (250 ng/ml, n=3) 
REC%=104.4 (500 ng/ml, n=3) 
REC%=104.2 (750 ng/ml, n=3) 
 
REC%=113.3 (n=24) 
REC%=113.2 (100 ng/ml, n=3) 
REC%=114.6 (250 ng/ml, n=6) 
REC%=117.0 (500 ng/ml, n=6) 
REC%=108.3 (750 ng/ml, n=6) 
Linearity 
             range 
             slope 
             y-intercept 
             coefficient of correlation 
 
0.25-200 g/ml 
0,07347 ± 0,002129 
0,1221 ± 0,05125 
R2=0.9967 
 
100-1000 ng/ml 
2.518e-005 ± 8.908e-7 
0.01141 ± 0.0005317 
R2= 0.9963 
1 LOD: limit of detection 2LOQ: limit of quantification 3 low, medium and high referred to the 
daptomycin concentration in the quality control samples which are indicated in brackets. 
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Table 3. Daptomycin concentrations in biological samples: comparison between plasma and breast 
milk concentrations [16] 
Sample Administration time Plasma (µg/ml) Breast milk (µg/ml) M/P ratio 
T0 500 mg - 0.229  
T6 - - 0.270  
T12 - - 0.269  
T241 500 mg - -  
T48 500 mg - 0.209  
T72 500 mg 44.4 0.186 0.004 
T78 - 199.07 0.329 0.002 
T84 - 65.85 0.329 0.005 
T96 - 64.21 0.243 0.004 
T120 - 19.89 0.121 0.006 
1no sample was collected at T24, but it has been included in the table as a time of administration. 
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Figure captions 
Figure 1. Chemical structure of erythromycin and daptomycin. 
Figure 2. An example of two chromatograms from plasma (sx) and milk (dx) showing both 
daptomycin and erythromycin.  
Figure 3. Analysis of daptomycin in blank matrix: plasma (A) and milk (B). The lack of interfering 
peaks at the retention time of daptomycin (depicted by black arrows) was considered as an 
acceptable selectivity.  
Figure 4. (A) Concentration profile of daptomycin vs time in both plasma and breast milk samples. 
Red arrows indicate the time in which daptomycin 500 mg was intravenously administered.  
(B) Ratio milk/plasma profile vs time, a ratio > 1 shows a prevalence distribution and accumulation 
in milk. 
